Furthermore, recent data strongly suggest that the benefit for the addition of chemotherapy in the adjuvant treatment is limited to p53mut EC, which includes most serous cancers but also a significant portion of other histologic subtypes such as carcinosarcomas, thus suggesting an escalation of adjuvant treatment with chemotherapy combined with radiation when p53 mutation is detected. This evidence concerns the gene TP53 and carcinosarcoma.